Item 2.02 Results of Operations and Financial Condition.

On January 6, 2023, Ocular Therapeutix, Inc. (the "Company") issued a press release (the "Release") to provide a business update. A copy of the Release is included as Exhibit 99.1 hereto and is incorporated by reference herein.

Although the Company is currently in the process of finalizing its financial results for the quarter and year ended December 31, 2022, the Company disclosed in the Release preliminary estimates as to net product revenue for the quarter and year ended December 31, 2022 and cash and cash equivalents as of December 31, 2022. The estimated net product revenue and cash and cash equivalents figures are based on preliminary and unaudited information and management's estimates as of the date of this Current Report on Form 8-K and are subject to completion of the Company's financial closing procedures. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimated net product revenue and cash and cash equivalents figures.

The information in this Current Report on Form 8-K is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits:




  99.1     Press Release of Ocular Therapeutix, Inc., dated January 6, 2023

104      Cover Page Interactive Data File (embedded within the Inline XBRL
         document)

© Edgar Online, source Glimpses